2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1169

Rapid Improvement with Tocilizumab in Refractory and Severe Uveitic Cystoid Macular Edema
Abstract Number: 1170

High Output Flow Cytometry Array Classifies Subjects with Uveitis Due to Behcet’s Disease and Sarcoidosis
Abstract Number: 1171

Mycophenolate Mofetil May Improve Interstitial Pneumonia with Autoimmune Features
Abstract Number: 1172

Utility of Interstitial Pneumonia with Autoimmune Features (IPAF) Proposed Criteria in the Classification of Patients with CTD-Associated Interstitial Lung Disease in a Single Centre
Abstract Number: 1173

Rheumatic Immune Related Adverse Events Due to Programmed Cell Death Protein 1 (PD-1) Inhibition for Cancer: Comprehensive Analysis of a Whole Cancer Cohort
Abstract Number: 1174

Which Definition Should be Used to Determine Colchicine Resistance in Patients with Familial Mediterranean Fever?
Abstract Number: 1175

Rituximab for Idiopathic and IgG4-Related Retroperitoneal Fibrosis
Abstract Number: 1176

A Randomized, Open-Label, Dose-Ranging Study of Oral Delayed Release Prednisone in Patients with Untreated Polymyalgia Rheumatica
Abstract Number: 1177

Airway Findings in Patients with Relapsing Polychondritis
Abstract Number: 1178

Sympathetic Joint Effusion in an Urban Hospital
Abstract Number: 1179

A Multi-Organ Inflammatory Condition with Features of Idiopathic Multicentric Castleman’s Disease and IgG4-Related Disease: An Unrecognized Mimicker of IgG4-RD
Abstract Number: 1180

Multicenter Study on the Rate of Renal Function Deterioration in IgG4-Related Tubulointerstitial Nephritis
Abstract Number: 1181

Serum KL-6 Level Reflects Severity of Interstitial Lung Disease Associated with Connective Tissue Disease
Abstract Number: 1182

Autoantibody Profiling in Prostvac and Ipilimumab Treated Prostate Cancer Patients Reveals Potential Biomarkers of Immune-Related Adverse Events
Abstract Number: 1183

Bone Sarcoidosis: A Multicenter Study

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].